SK Pharmteco Completes Obesity-Drug API Plant, Sets Up Peptide CDMO Clash With Samsung
View of SK Biotek’s Sejong plant, a subsidiary of SK Pharmteco. Photo courtesy of SK Pharmteco SK Biotek,…
Samsung Biologics Acquires PolyPeptide for 2.7 Trillion Won, Expanding Growth Axis Beyond Antibodies
PolyPeptide Group’s India (Ambernath) plant. Photo courtesy of Samsung Biologics Samsung Biologics’ (207940.KS) acquisition of Swiss peptide contract…
Samsung Biologics Secures Peptide Capacity in Bid to Lead Obesity Drug CDMO
Samsung Biologics (207940.KS) has made the largest investment in the history of Korean pharmaceutical and biotech mergers and…
Samsung Biologics Acquires Swiss Peptide CDMO PolyPeptide Group for approximately $1.8 Billion — BigGo Finance
Samsung Biologics (207940) has placed a major bet on capturing the global peptide contract development and manufacturing organization…
Samsung Biologics to Acquire Peptide CDMO for 2.7 Trillion Won
A view of Samsung Biologics’ Plant 4. Photo courtesy of Samsung Biologics Samsung Biologics (207940.KS) is moving to…
Samsung Biologics Shares Slip Early After 2.7 Trillion Won Acquisition
A view of Samsung Biologics’ Plant 4. Samsung Biologics Samsung Biologics (207940.KS) has agreed to acquire a global…
Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a global peptide contract development…